World Library  
Flag as Inappropriate
Email this Article

Flunarizine

Article Id: WHEBN0006091357
Reproduction Date:

Title: Flunarizine  
Author: World Heritage Encyclopedia
Language: English
Subject: ATC code N07, Nefopam, Janssen Pharmaceutica, Histaminergic, Sodium channel blocker
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Flunarizine

Flunarizine
Systematic (IUPAC) name
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
Clinical data
AHFS/Drugs.com
Identifiers
CAS Registry Number  YesY
ATC code N07
PubChem CID:
DrugBank  YesY
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  YesY
Synonyms 1-[bis(4-fluorophenyl)methyl]-4-cinnamyl-piperazine
Chemical data
Formula C26H26F2N2
Molecular mass 404.495
 YesY   

Flunarizine is a drug classified as a calcium channel blocker.[1] Flunarizine is a non-selective calcium entry blocker with other actions including histamine H1 receptor blocking activity. It is effective in the prophylaxis of migraine,[2] occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia, as well as being effective in rapid onset dystonia-parkinsonism (RDP). Both these conditions share a mutation in the ATP13A gene; flunarizine is not available by prescription in the U.S. or Japan.[3] Flunarizine has been shown to significantly reduce headache frequency and severity in both adults and children. Flunarizine was discovered at Janssen Pharmaceutica in 1968.

Side effects and contraindications

Flunarizine has some side effects including weight gain, extrapyramidal effects, drowsiness and depression, it is contraindicated in hypotension, heart failure and arrhythmia. Flunarizine use is avoided in patients with depression, severe constipation or those with extrapyramidal disorders.

References

  1. ^ Calium channel blocker
  2. ^ Effective in migraine
  3. ^ ATP13A mutation,and response to flunarizine

External References


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.